- Published on
Medicine – Multiple Myeloma
Multiple myeloma is a malignant plasma cell disorder characterised by clonal proliferation of plasma cells within the bone marrow and production of a monoclonal immunoglobulin (paraprotein) or free light chains.
The disease may cause diffuse bone marrow infiltration, focal osteolytic lesions, renal impairment, anaemia and increased susceptibility to infections.
It predominantly affects older adults, with a median age at diagnosis of approximately 69–70 years.
Multiple myeloma is a plasma cell malignancy that causes organ damage through bone marrow infiltration, abnormal monoclonal protein production and increased osteoclast-mediated bone resorption.
1. Aetiology and Pathophysiology
Multiple myeloma develops from malignant transformation of a plasma cell clone, usually preceded by monoclonal gammopathy of undetermined significance (MGUS).
The malignant plasma cells accumulate within the bone marrow and produce monoclonal immunoglobulins or free light chains.
Mechanisms of Organ Damage
- Bone destruction: Myeloma cells stimulate osteoclast activity and suppress osteoblast activity, producing osteolytic lesions.
- Anaemia: Bone marrow infiltration and impaired erythropoiesis.
- Renal impairment: Frequently caused by free light-chain cast nephropathy; hypercalcaemia, dehydration and amyloidosis may also contribute.
- Infection: Suppression of normal immunoglobulin production, known as immunoparesis.
- Amyloidosis: Some plasma cell clones produce light chains capable of forming AL amyloid deposits.
Pathophysiology Flowchart
2. Types of Paraproteins
Myeloma cells produce monoclonal immunoglobulins or free light chains. The major types are:
| Paraprotein Type | Approximate Frequency |
|---|---|
| IgG | 50–60% |
| IgA | 20–25% |
| Light-chain-only myeloma | 15–20% |
| IgD, IgE, IgM or other rare types | Uncommon |
The exact proportions vary between populations and diagnostic series.
3. Clinical Features
A. Bone Pain
Bone pain is one of the most common presenting symptoms of multiple myeloma.
Typical sites include:
- Vertebral column, particularly the lower back.
- Ribs.
- Pelvis.
- Shoulders.
- Long bones.
Complications include pathological fractures, vertebral compression fractures and spinal cord compression.
B. Renal Impairment
Renal dysfunction may result from:
- Free light-chain cast nephropathy.
- Hypercalcaemia.
- Dehydration.
- AL amyloidosis.
- Monoclonal immunoglobulin deposition disease.
- Nephrotoxic medications.
C. Anaemia
Anaemia is usually normocytic and normochromic.
Symptoms include fatigue, pallor, weakness and exertional dyspnoea.
D. Recurrent Infections
Patients are particularly susceptible to bacterial respiratory and urinary tract infections because normal immunoglobulin production is suppressed.
E. Amyloidosis
Associated AL amyloidosis may cause:
- Nephrotic syndrome.
- Restrictive cardiomyopathy.
- Peripheral neuropathy.
- Macroglossia.
4. CRAB Features
The classic manifestations of myeloma-related end-organ damage are remembered using the mnemonic CRAB.
| Letter | Feature | Clinical Manifestations |
|---|---|---|
| C | Hypercalcaemia | Thirst, constipation, confusion, dehydration |
| R | Renal impairment | Reduced renal function, acute kidney injury |
| A | Anaemia | Fatigue, pallor, dyspnoea |
| B | Bone lesions | Osteolytic lesions, bone pain, pathological fractures |
CRAB Illustration
5. Investigations
A. Blood Investigations
| Investigation | Typical Finding |
|---|---|
| Full blood count | Normocytic normochromic anaemia |
| ESR | Often markedly elevated |
| Serum calcium | May be elevated |
| Renal function | Elevated creatinine or reduced eGFR |
| Total serum protein | May be elevated |
| Albumin | May be reduced |
| Serum protein electrophoresis | Monoclonal protein (M-spike), if detectable |
| Serum immunofixation | Identifies monoclonal immunoglobulin type |
| Serum free light chains | Abnormal kappa/lambda ratio |
| Beta-2 microglobulin | Used in prognostic staging |
B. Urine Investigations
Bence Jones proteins are monoclonal free immunoglobulin light chains excreted in urine.
Urine protein electrophoresis and immunofixation may identify urinary monoclonal light chains.
A negative urine test does not exclude multiple myeloma.
C. Bone Marrow Examination
Bone marrow aspiration and biopsy may demonstrate:
- Increased clonal plasma cells.
- Plasma cell infiltration of the bone marrow.
- Kappa or lambda light-chain restriction.
- Cytogenetic abnormalities relevant to prognosis.
A bone marrow clonal plasma cell proportion of at least 10%, or a biopsy-proven plasmacytoma, is part of the standard diagnostic framework for active multiple myeloma.
D. Imaging
Characteristic imaging findings include:
- Punched-out osteolytic lesions.
- Vertebral compression fractures.
- Pathological fractures.
- Diffuse or focal marrow involvement.
The classical pepper-pot skull appearance refers to multiple small punched-out lesions on skull radiographs.
Modern whole-body low-dose CT, MRI or PET/CT is generally preferred over conventional skeletal surveys for initial assessment.
6. Diagnostic Criteria – SLiM-CRAB
Active multiple myeloma is diagnosed when there are at least 10% clonal bone marrow plasma cells or a biopsy-proven plasmacytoma, together with at least one myeloma-defining event.
These events include CRAB features attributable to the plasma cell disorder or one of three biomarkers remembered by SLiM.
| Criterion | Myeloma-Defining Finding |
|---|---|
| S | Clonal bone marrow plasma cells ≥60% |
| Li | Involved/uninvolved serum free light-chain ratio ≥100, with involved light chain ≥100 mg/L |
| M | More than one focal lesion on MRI, each ≥5 mm |
| C | Hypercalcaemia meeting diagnostic thresholds |
| R | Renal impairment meeting diagnostic thresholds |
| A | Anaemia meeting diagnostic thresholds |
| B | One or more qualifying osteolytic bone lesions |
Diagnostic Flowchart
7. Differential Diagnosis
| Disorder | Distinguishing Feature |
|---|---|
| MGUS | Monoclonal protein without myeloma-defining events; lower clonal burden |
| Smouldering myeloma | Higher clonal burden but no myeloma-defining events |
| Waldenström macroglobulinaemia | Usually IgM paraprotein with lymphoplasmacytic lymphoma |
| Metastatic bone malignancy | Bone lesions without typical clonal plasma cell findings |
| AL amyloidosis | Organ deposition of amyloidogenic light chains |
8. Management of Multiple Myeloma
Treatment depends on symptoms, frailty, renal function, cytogenetic risk, transplant eligibility and access to available therapies.
A. Supportive Treatment
- Analgesia for bone pain, avoiding nephrotoxic drugs where possible.
- Appropriate hydration and treatment of hypercalcaemia.
- Bisphosphonates or denosumab for myeloma-related bone disease when indicated.
- Blood transfusion for symptomatic severe anaemia.
- Infection prevention and prompt treatment.
- Local radiotherapy for selected painful bone lesions or plasmacytomas.
- Urgent assessment of suspected spinal cord compression.
- Management of renal impairment, including rapid reduction of light-chain production.
B. Anti-Myeloma Drug Therapy
Modern treatment generally involves combinations of agents such as:
- Proteasome inhibitors: Bortezomib and carfilzomib.
- Immunomodulatory drugs: Lenalidomide and pomalidomide.
- Corticosteroids: Dexamethasone.
- Monoclonal antibodies: Daratumumab and other agents.
- Alkylating agents: Cyclophosphamide and melphalan.
A commonly used combination is daratumumab, bortezomib, lenalidomide and dexamethasone (D-VRd), where appropriate and available.
C. Autologous Stem Cell Transplantation
Selected fit patients may undergo high-dose chemotherapy followed by autologous haematopoietic stem cell transplantation.
The procedure uses the patient's own collected stem cells to restore bone marrow function after intensive chemotherapy.
D. Relapsed or Refractory Disease
Depending on prior treatment and eligibility, options may include alternative drug combinations, CAR-T-cell therapy and bispecific antibodies.
Multiple myeloma is generally treatable but not routinely curable, and relapse remains common.
Treatment Flowchart
9. Important Complications
- Pathological fractures.
- Spinal cord compression.
- Acute kidney injury and chronic kidney disease.
- Severe hypercalcaemia.
- Recurrent or severe infections.
- AL amyloidosis.
- Hyperviscosity syndrome, less common than in Waldenström macroglobulinaemia.
- Venous thromboembolism, including treatment-associated risk.
10. High-Yield Examination Summary
| Feature | Key Point |
|---|---|
| Disease | Malignant plasma cell neoplasm |
| Typical age | Around 70 years |
| Most common paraprotein | IgG |
| Bone abnormality | Punched-out osteolytic lesions |
| Blood film | Rouleaux formation may occur |
| ESR | Often markedly elevated |
| Urine protein | Bence Jones free light chains |
| Renal disease | Commonly light-chain cast nephropathy |
| Diagnostic mnemonic | SLiM-CRAB |
| Bone marrow | Clonal plasma cell proliferation |
| Treatment | Combination anti-myeloma therapy ± autologous stem cell transplantation |
11. Key Examination Pearls
- Multiple myeloma is a plasma cell malignancy producing monoclonal immunoglobulins or free light chains.
- IgG is the most common paraprotein type.
- Bone pain, particularly in the back and ribs, is a common presentation.
- Osteolytic lesions occur because osteoclast activity is increased.
- Renal impairment commonly results from free light-chain cast nephropathy.
- Anaemia results from marrow involvement and other disease-related mechanisms.
- Normal antibody production is suppressed, increasing susceptibility to infection.
- Bence Jones proteins are monoclonal free light chains in urine.
- A high ESR and rouleaux formation are supportive but not diagnostic.
- Diagnosis requires demonstration of a clonal plasma cell disorder and myeloma-defining events.
- Modern treatment uses combination drug therapy, with autologous stem cell transplantation in eligible patients.
An older patient presenting with persistent back pain, anaemia, renal impairment, hypercalcaemia and punched-out osteolytic lesions should raise strong suspicion of multiple myeloma. Confirm the diagnosis using monoclonal protein studies, serum free light chains, bone marrow assessment and appropriate imaging.
Suspected spinal cord compression, severe hypercalcaemia, acute kidney injury or serious infection in a patient with multiple myeloma requires urgent medical assessment. Treatment should be individualised by a specialist haematology team.
Kembara Xtra – Medicine Revision Notes